Abstract:Abstract The median survival time for newly diagnosed patients with glioblastoma (GBM) is 15 months, highlighting the need for improved therapies. Current treatment for newly diagnosed and recurrent GBM consists of tumor resection and chemoradiation therapy. The immunosuppressive tumor microenvironment (TME) is a central obstacle in the treatment of GBM. Lack of NK cell and CD8+ T cell infiltration prevents efficacy with immunotherapies like immune checkpoint blockade (ICB).One approach our lab is pursuing to enhance tumor infiltrating lymphocytes is through harnessing the anti-viral cGAS-STING pathway. Upon cGAS activation by cytosolic double stranded DNA, the TBK1 kinase is phosphorylated, initiating a subsequent type I interferon (IFN) response and the recruitment of immune cells. This pathway is commonly altered in many cancer types to evade immune activation. Our lab has demonstrated survival benefits with STING agonist treatment in immunocompetent GBM mouse models. We have also shown strong STING localization in the vasculature, implicating endothelial cells as a potential treatment target for anti-tumor efficacy. Here we investigated the potential role of tumor vasculature in mediating the effects of STING agonists in GBM therapy.We have shown robust cGAS-STING activation in brain endothelial cell lines through enhanced secretion of CXCL10, IFN-β, and RANTES upon STING agonist treatment in vitro. Western blotting also shows pathway activation in response to treatment through increased phospho-TBK1 levels. Activation was further potentiated by manganese.To investigate the effects of STING activation in brain endothelial cells in detail, we performed RNA sequencing. This showed 262 differentially expressed genes in response to pharmacologic cGAS-STING activation, with 183 of these being upregulated. The top gene ontology terms enriched include type I interferon signaling pathway, defense response to virus, and antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent. In addition, gene expression of tight junction protein Claudin 5 was also enhanced. We have also shown increased resistance in response to activation, through transendothelial electrical resistance (TEER) assays. Taken together, these results suggest that cGAS-STING activation in endothelial cells leads to tight junction remodeling in addition to immunomodulatory changes, implicating roles for endothelial cells in barrier function and immune cell interactions respectively. Current research in our lab focuses on elucidating the mechanisms behind these changes. Our goal is to identify beneficial endothelial cell changes which promote anti-tumor immunity in order to inform future treatment strategies. We are currently performing studies aimed at demonstrating that cGAS-STING activation in endothelial cells is critical for the efficacy of STING agonist treatment. Citation Format: Andrea Schmidt, Sandra Remson, Philippa Vaughn-Beaucaire, Jorge L. Jimenez-Macias, Praveen Srinivasan, Maximillian Pinho-Schwermann, Sean Lawler. Brain derived endothelial cells as a mediator of cGAS-STING driven anti-tumor efficacy in glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2457.

Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages

Tumor-derived extracellular vesicles: how they mediate glioma immunosuppression

Glioma-derived small extracellular vesicles induce pericyte-phenotype transition of glioma stem cells under hypoxic conditions

Immunopathology of Extracellular Vesicles in Macrophage and Glioma Cross-Talk

Extracellular vesicles produced by irradiated endothelial or Glioblastoma stem cells promote tumor growth and vascularization modulating tumor microenvironment

Immunomodulatory effects of extracellular vesicles in glioblastoma

Decoding the secret of extracellular vesicles in the immune tumor microenvironment of the glioblastoma: on the border of kingdoms

Extracellular vesicles as modulators of glioblastoma progression and tumor microenvironment

Abstract 2457: Brain derived endothelial cells as a mediator of cGAS-STING driven anti-tumor efficacy in glioblastoma

Cell-to-cell communications of cGAS-STING pathway in tumor immune microenvironment.

Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression

Hypoxic glioma-derived exosomes promote M2-like macrophage polarization by enhancing autophagy induction

A tale of two tumors: differential, but detrimental, effects of glioblastoma extracellular vesicles (EVs) on normal human brain cells

Molecular profiles and immunomodulatory activities of glioblastoma-derived exosomes

Interplay Between V-ATPase G1 and Small EV-miRNAs Modulates ERK1/2 Activation in GBM Stem Cells and Nonneoplastic Milieu

Extracellular Vesicles Derived from Glioma Stem Cells Affect Glycometabolic Reprogramming of Glioma Cells Through the miR-10b-5p/PTEN/PI3K/Akt Pathway

Role of Tumor-Derived Extracellular Vesicles in Glioblastoma

ICAM‐1‐Expressing Extracellular Vesicles Enable Sequential Delivery Barrier‐Breaking and Microenvironment Modulating for Glioblastoma Stem Cell Inhibition

Exosome‐transmitted podoplanin promotes tumor‐associated macrophage‐mediated immune tolerance in glioblastoma

Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways

Abstract 2959: Signatures of therapy-induced senescence in glioblastoma-derived extracellular vesicles